Rankings
▼
Calendar
FULC Q3 2025 Earnings — Fulcrum Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
FULC
Fulcrum Therapeutics, Inc.
$436M
Q3 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$22M
Net Income
-$20M
EPS (Diluted)
$-0.31
QoQ Revenue Growth
NaN%
Cash Flow
Operating Cash Flow
-$14M
Free Cash Flow
-$14M
Stock-Based Comp.
$0
Balance Sheet
Total Assets
$215M
Total Liabilities
$16M
Stockholders' Equity
$198M
Cash & Equivalents
$47M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$0
—
Gross Profit
$0
$0
—
Operating Income
-$22M
-$25M
+13.0%
Net Income
-$20M
-$22M
+9.7%
← FY 2025
All Quarters
Q4 2025 →